Description
A little noticed FDA report reveals internal opposition to Trump plans to speed drugs to market. Peter Doshi discusses the concernsCitation
Doshi, P.(2017). FDA unease about faster drug approval. BMJ 2017;357:j1691. DOI: https://doi.org/10.1136/bmj.j1691Keyword
drug safety studiesdrug regulations
clinical trials, phase 3
United States. Food and Drug Administration
Clinical Trials as Topic
Clinical Trial, Phase III
Identifier to cite or link to this item
http://hdl.handle.net/10713/6594ae974a485f413a2113503eed53cd6c53
10.1136/bmj.j1691